Matching safety to access: global actors and pharmacogovernance in Kenya- a case study

Kathy Moscou1,4,5 and Jillian C. Kohler1,2,3,4

Abstract

Background: The Kenyan government has sought to address inadequacies in its National Pharmaceutical Policy and the Pharmacy and Poisons Board’s (PPB) medicines governance by engaging with global actors (e.g. the World Health Organization). Policy actors have influenced the way pharmacovigilance is defined, how challenges are understood and which norms are requisite to address drug safety issues. In this paper, we investigate the relationship between specific modes of engagement among global (exogenous) and domestic actors at the national and sub-national level to identify the positive or negative effect on pharmacovigilance and pharmacogovernance in Kenya. Pharmacogovernance is defined as the manner in which governing structures; policy instruments; institutional authority (e.g., ability to act, implement and enforce norms, policies and processes) and resources are managed to promote societal interests for patient safety and protection from adverse drug reactions (ADRs). Qualitative research methods that included key informant interviews and document analysis, were employed to investigate the relationship between global actors’ patterns of engagement with national actors and pharmacogovernance in Kenya.

Results: Global actors’ influence on pharmacogovernance and pharmacovigilance priorities in Kenya (e.g., legislation and adverse drug reaction surveillance) was positively perceived by key informants. We found that global actors’ engagement with state actors produced positive and negative outcomes. Engagement with the PPB and Ministry of Health (MOH) that was characterized as dependent (advocacy, empowerment, delegated) or interdependent (collaborative, cooperative, consultative) was mostly associated with positive outcomes e.g., capacity building; strengthening legislation and stakeholder coordination. Fragmentation (independent engagement) hindered risk communication between public, private, and NGO health programs.

Conclusion: A framework for assessing pharmacogovernance would support policy makers’ evidence-based decision making regarding investments to strengthen capacity for pharmacovigilance and guide policies regarding the state and exogenous actor relationship pertaining to pharmacogovernance. Ideally, dependency on exogenous actors should be reduced while retaining consultative, collaborative, and cooperative engagement when inter-dependency is appropriate. The use of global actors to address Kenya’s pharmacovigilance inadequacies leaves the country vulnerable to 1) ad hoc drug surveillance; 2) pharmacovigilance fragmentation; 3) shifting priorities; and 4) cross purpose interests.

Keywords: Drug safety, Global actors, Governance, Kenya, Pharmacovigilance, Regulation

* Correspondence: kathy.moscou@utoronto.ca
1Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON M5S 3M2, Canada
4WHO Collaborating Centre for Governance, Accountability and Transparency for the Pharmaceutical Sector, University of Toronto, 144 College Street, Toronto, ON M5S 3M2, Canada

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Pharmacogovernance is essential to policy choices (or lack thereof), infrastructure, institutional authority and resources to address pharmaceutical safety and safeguard public health. It is defined as the manner in which governing structures; policy instruments; institutional authority (e.g., ability to act, implement and enforce norms, policies and processes) and resources are managed to promote societal interests for patient safety and protection from adverse drug reactions (ADRs) [1]. Weak pharmacogovernance negatively affects patient safety because it can lead to a failure to adopt legislation and norms for pharmacovigilance resulting in poor quality medicines in the supply chain. It is costly when limited healthcare resources are wasted on increasing medicines costs; some of which may be unsafe or ineffective [2–5].

In Kenya, the Ministry of Health is responsible for governing the safety of medicines. The Ministry delegates this responsibility specifically to one of its institutions - the Pharmacy and Poisons Board (PPB). The PPB was established by Parliament in 1957 under the Pharmacy and Poisons Act, Chapter 244 [6]. It is a semi-independent regulatory authority [7]. The PPB’s stated mission is to ‘safeguard the health of the public by ensuring that medicines and health products comply with acceptable standards of quality, safety and efficacy’ [8]. PPB’s mission complements the Kenya Health Policy and the Constitution of Kenya which expresses that ‘every person has the right to the highest attainable standard of health’ [Kenya Bill of Rights Article 43 (1)(a)], and ‘consumers have the right (a) to goods and services of reasonable quality; (b) to the information necessary for them to gain full benefit from goods and services; (c) to the protection of their health, safety, and economic interests’ [Bill of Rights Article 46 (1)] [9, 10].

Kenya’s National Drug Policy, Pharmacy and Poisons Act [Rev. 2012], Food, Drug and Chemical Substance Act [Rev. 2012] (FDCSA), and Public Health Act are the key policy and enabling legislation regulating pharmaceuticals in Kenya.

The allocation of financial and human resources needed to support patient safety and protect the public from ADRs is another key component of pharmacogovernance. The PPB can generate revenues to support its activities by collecting fees from pharmaceutical companies for licensing and product registration as permitted by the Pharmacy and Poisons Act. The PPB also receives funding from the national government and ad hoc contributions from international actors such as the European Commission and United States Agency for International Development (USAID) [11, 12]. Human resources are not apportioned equally to PPB’s six Directorates. Staffing is greatest in the Directorates of Business Support (46) and Pharmaceutical Inspectorate, Surveillance, and Enforcement (62). In contrast, fewer staff are allocated to the Directorates of Medicine Information and Pharmacovigilance (5) and Quality Control (2) [11]. Each Directorate is allocated an operating budget by PPB. Some Directorates receive greater funding than others depending on PPB and Ministry of Medical Services priorities. The percentage of PPB’s funding that is allocated to pharmacovigilance is unknown. Funding levels needed to meet PPB’s strategic goals for pharmacovigilance are not reported in the Pharmacy and Poisons Board Strategic Plan 2014–2019 [11].

Pharmacogovernance and exogenous actors in Kenya
The Kenyan National Pharmaceutical Policy calls for international collaboration and effective partnerships to address pharmaceutical sector issues and to safeguard public health and safety’ [13]. The policy is aligned with Kenya’s national governance that permits the delegation of authority to exogenous (external and non-state) actors to create infrastructure and implement domestic programs that increase national capacity to provide services. They comprise two of the three pillars of the Kenya Health Sector Strategic and Investment Plan (KHSSP) implementation framework: state actors, non-state actors, and external actors [7]. Extern- al actors (e.g., bilateral, multilateral, or philanthropic actors), non-state actors (e.g., faith-based organizations, civil society organizations and nongovernmental organizations [NGOs]), international NGOs (INGOs) and not-for-profit NGOs are described in the Kenya Health Sector Strategic and Investment Plan (KHSSP) as ‘crucial partners, both as a financial resource for the health sector and as a way of ensuring programme delivery competencies’ (p.31) to augment limited domestic human resources in the Kenya Health Policy 2012–2030 strategic vision [7, 10].

In 2014, there were more than 7000 NGOs registered in Kenya; most were funded by international donors [14, 15]. NGOs and faith-based organizations provided approximately 14% of health care services in Kenya [16–18]. Other providers of health care services in Kenya are public institutions run by the government (e.g., the Ministry of Health, military, prisons, or state corporations), private facilities, academic institutions and parastatals. The majority of Kenya’s health facilities are public institutions (48%) or private facilities (37%) [17]. Exogenous actors influencing pharmaceutical policy and programs in Kenya include the World Health Organization (WHO), United States Agency for International Development (USAID) and Management Sciences for Health (MSH) [19].
Exogenous actors: benefits

The government of Kenya has sought engagement with exogenous actors to address some of the weaknesses of the country’s National Pharmaceutical Policy and PPB’s pharmacogovernance in order to combat deficiencies that leave the country vulnerable to substandard, spurious, falsely labelled, falsified and counterfeit (SSFFCs) medicines entering the supply chain. This strategy is a rational one given that dealing with SSFFCs is an issue that goes well beyond one nation’s borders and requires collective action on the part of many stakeholders. For example, in 2011, SSFFC drugs found in Kenya’s supply chain included the oral contraceptive Postinor-2™ (levonorgestrol) and 15,000 of batches of the antiretroviral Zidolam-N™ (zidovudine) [20]. What is troubling about this example is that the SSFFC antiretroviral medicines that entered the supply chain were not distributed by nefarious groups but rather inadvertently distributed to patients by Médecins Sans Frontières [21].

Kenya has therefore engaged with global actors to increase its capacity to identify SSFFCs, analyze drug safety signals and enhance risk communication [6, 22]. Their resources contributed to advancements in postmarket drug safety by supporting the development of ADR reporting tools (e.g. USAID funding to develop PPB’s online ADR reporting system) and pharmacovigilance training to build capacity for pharmacosurveillance [6]. NGO’s technical support and financial resources enabled active pharmacovigilance employing cohort event monitoring (CEM) and targeted spontaneous reporting (TSR) (e.g., the Academic Model Providing Access to Healthcare [AMPATH] pharmacovigilance program at Moi Teaching and Referral Hospital in Eldoret, Kenya). Donor-run health programs have enhanced pharmacovigilance because the programs have pharmacovigilance requirements not mandated by the public sector [22].

Exogenous actors such as the New Partnership for Africa’s Development (NEPAD) African Medicines Regulatory Harmonization (AMRH) Programme have contributed to regulatory governance through the creation of Regional Centres of Regulatory Excellence (RCOREs). In 2014, the Kenya Pharmacy and Poisons Board was designated a RCORE for pharmacovigilance. Kenya is also a member of the East African Community (EAC) which advocates for harmonization and regulatory convergence pertaining to pharmacovigilance [23].

Exogenous actors: risks

There is generally good will among state and NGO actors who are perceived as instrumental in implementing policy and programs in Kenya [14]. Olsson, Dodoo and Pal (2015) positively describe numerous examples of global actors’ interventions to catalyze awareness of pharmacovigilance and expand capacity for pharmacovigilance. However, the parallel donor-run health programs that are positively received for mandating pharmacovigilance are also described as negatively contributing to fragmentation in the health system [13]. A key governance challenge, cited in the Sessional Paper for Kenya’s National Pharmaceutical Policy, is overcoming a ‘lack of effective coordination leading to fragmentation and duplication’ of services which is coupled with ‘inadequate technical oversight of private, mission and NGO pharmaceutical service providers’ [13]. Parallel systems for collecting data about ADRs and adverse vaccine reactions coupled with poor data exchange and communication hinder comprehensive pharmacovigilance in many low- and middle income countries [22].

Theoretical framework

We employ Network Governance Theory to explain how and why state and exogenous actors form networks in order to advance postmarket drug safety in Kenya. Network Governance Theory proposes that stakeholders may form policy networks to address complex problems that are uncertain, require specialized knowledge, are multi-jurisdictional and have high potential for risk or conflict which members perceive are best solved collectively [24]. Network Governance Theory is germane to pharmacogovernance in Kenya where a network of relevant stakeholders contributes to shared policy making. Pharmacogovernance policy and practice are shaped by networks of domestic and global actors who have an influence on the way pharmacovigilance is defined, how challenges are understood and which norms are requisite to address drug safety issues [24, 25]. Many of the exogenous actors that contribute to pharmacogovernance in Kenya are the same non-state and external actors outlined in the KHSSP implementation framework. They contribute to governance through their representation in the Kenya Aid Effectiveness Group (AEG). The AEG is comprised of representatives of the Government of Kenya (GoK) and 17 development partners from 13 countries and the European Commission, the United Nations and the World Bank Group [26]. The AEG serves as a platform for exogenous actors to contribute to governance in Kenya by guiding the joint development GoK-development partner framework for addressing and monitoring issues of mutual accountability [26]. Intergovernmental organizations (IGO), technical INGOs and philanthropic organizations contributing to pharmacogovernance include:
advance pharmacovigilance (Table 1) [6, 19, 27].

The establishment of training centres for pharmacovigilance governance and advocacy for legislation to

for Kenya’s pharmaceutical sector influenced the draft Guidelines for Kenya’s National Pharmacovigilance System, informed drug safety policies and recommendations for the

for Africa’s Development (NEPAD) Regional Centers for Regulatory Excellence and pharmaceutical companies. Their contribution to assessment of Kenya’s pharmaceutical sector influenced the draft Guidelines for Kenya’s National Pharmacovigilance System, informed drug safety policies and recommendations for the establishment of training centres for pharmacovigilance governance and advocacy for legislation to advance pharmacovigilance (Table 1) [6, 19, 27].

Network actor relationships

Exogenous actors have the potential to continue influencing pharmacogovernance in Kenya given their strong participation in health policy networks. The state-NGO’s relationship however is in a state of flux. The NGO Coordination Act, which was enacted in 1990 and revised in 2012 to coordinate the work of national and international NGOs operating in Kenya, increase oversight, reduce fragmentation in the healthcare system and provide policy guidelines regarding harmonization of activities for the national development plan for Kenya, through a NGO Coordination Board, was repealed and replaced by the Public Benefit Organization (PBO) Act, passed January, 2013 [28]. The PBO Act provides clear definitions for what is and is not a PBO and what type of activities that PBOs can and cannot engage in. PBO activities include: enhancing or promoting the economic, environmental, social or cultural development or protecting the environment or lobbying or advocating on issues of general public interest or the interest or well-being of the general public or a category of individuals or organizations [29]. While the country continues to recognize ‘the importance of mutual co-existence and the need to work together [with NGOs]’ [29], editorials have suggested that the Kenyan government has been pushing forward constitutional amendments such as the new PBO Act, to ‘shrink the political and legal space in which they operate’ [30].

A framework for understanding the state and exogenous actor relationships pertaining to pharmacogovernance is critical, given Kenya’s past and current dependence on exogenous actors as implementing partners. We thus investigated the relationships between specific modes of engagement amongst exogenous and domestic actors at the national and subnational level to identify the positive or negative effect on pharmacogovernance and pharmacovigilance. The research question addressed through this study is: Which pattern(s) of engagement among exogenous actors, the Kenya Pharmacy and Poisons Board and county actors enable or hinder pharmacogovernance and pharmacovigilance?

We analyzed dependent, independent, and interdependent patterns of engagement amongst state and exogenous in Kenya. We defined dependency as relying on others for financial or other support. Dependency is an asymmetrical relationship whereby global and domestic actors with resources and political power are able to influence policies and processes in tandem with or in conflict with the interests of lessor resourced local groups [31]. Independence was defined as not depending on another’s authority or resources for support. In interdependent modes of engagement each partner benefits by reliance on the other. Interdependence between actors may be equal and mutually dependent (symmetrical) or asymmetrical [32]. The actions or national policies of one partner are perceived to have a direct effect on the other members, although the policies may benefit partners disproportionately [32]. Kenya is a robust example to examine because of the numerous internationally funded nongovernmental organizations (NGOs) operating in the country and their high level of integration into Kenya’s governance [14].

Our paper is organized as follows. First, we provide background regarding pharmacogovernance and global actors in Kenya. Second, we describe our research methods. Third, we analyze exogenous actors’ motivation for engaging with state actors to advance pharmacovigilance and pharmacogovernance. Fourth, state and exogenous actors’ perceptions of pharmacogovernance and drug safety are analyzed. Finally, the patterns of engagement between state and exogenous actors are characterized and analyzed.

Methods

Key informant interviews and a documentary analysis were conducted to investigate the patterns of engagement between state and exogenous actors affecting pharmacogovernance and pharmacovigilance in Kenya. Purposive and reputational sampling strategies were employed to select participants able to provide rich data about pharmacovigilance systems in Kenya. The participants were identified via a ‘snow-balling’ process. Thirteen key informants were interviewed which represented the calculated quota sample. Quota sampling is a non-probabilistic sampling method used to determine the minimum representative sample size [33]. In this case study, a quota sample representing location (rural, urban), pharmacovigilance resources (high resourced, low resourced) and sector representation (regulatory), government (national, external [IGO]), pharmaceutical manufacturer, non-state actor, non-governmental organization (national, international) was interviewed. The key informants included representatives of the Kenya medicines
| Exogenous actors                          | Governance network | Agency | Pharmacogovernance in Kenya |
|------------------------------------------|--------------------|--------|----------------------------|
| Denmark                                  | AEG, SWG           | Danish International Development Agency | • Kenya National Pharmaceutical Policy- 2008 [14]  
• Framework for addressing and monitoring issues of accountability [13] |
| Germany                                  | AEG                | Deutsche Gesellschaft für Technische Zusammenarbeit | • Framework for addressing and monitoring issues of accountability [13] |
| Japan                                    | AEG, SWG           | Japanese International Cooperation Agency | • Corporate governance and technical, financial support  
• Framework for addressing and monitoring issues of accountability [13] |
| United Kingdom                           | AEG                | Department for International Development [UK] | • Kenya National Pharmaceutical Policy- 2008 [14]  
• Framework for addressing and monitoring issues of accountability [13] |
| United Nations                           | AEG, SWG           | United Nations Children’s Fund, United Nations Population Fund | • Corporate governance and technical, financial support [11]  
• Framework for addressing and monitoring issues of accountability [13] |
| United States                            | AEG, SWG           | United States Agency for International Development, US President’s Emergency Programme for AIDS Relief, US Pharmacopoeia, Center for Disease Control | • National Pharmacovigilance Guidelines (USP) [6]  
• Corporate governance and technical, financial support [11]  
• Framework for addressing and monitoring issues of accountability [13] |
| European Commission                      | AEG                | Monitoring Medicines Project FP7 | • Kenya National Pharmaceutical Policy- 2008 [14]  
• Normative framework for pharmaco surveillance [44]  
• Framework for addressing and monitoring issues of accountability [13] |
| World Bank                               | AEG                | World Bank | • Assessment of the pharmaceutical sector and support for updating policy frameworks [14]  
• Corporate governance and technical, financial support [11] |
| Global Fund                              |                    | Global Fund | • Corporate governance and technical, financial support [11]  
• Pharmacovigilance norms [17, 45] |
| New Partnership for Africa’s Development (NEPAD) | AMRH              | AMRH | • Regional Centre for Regulatory Excellence in Pharmacovigilance [11, 15] |
| Management Sciences for Health           | PPB and MoH SAGs, County HMT | United States Agency for International Development | • Kenya National Pharmaceutical Policy- 2008 [14]  
• Kenya National Pharmacovigilance Guidelines- Draft [6] |
| Non-state actors                         | HSWG, PPB and MoH SAGs | World Health Organization (WHO) | • Kenya National Pharmacovigilance Guidelines- Draft [6]  
• Kenya National Pharmaceutical Policy- 2008 [14] |
regulatory authority (Pharmacy and Poisons Board), multinational and domestic pharmaceutical corporations, IGOs/INGOs and pharmacy and Kenyan government representatives from Turkana County, Uasin Gishu County, Mombasa County and Kwale County.

The county key informants that were interviewed represented a convenience sample of information-rich individuals from urban and rural counties. The sample was selected to characterize regional differences in pharmacogovernance and pharmacovigilance in Kenya. See Table 2.

Interviews were conducted in person or by SKYPE between March 2014 and January 2015 following ethics approval from the University of Toronto, Canada and Moi University, Kenya. Informed consent including consent to publish the information they provided was obtained from study participants. Interviews were conducted until saturation of themes was reached. All interviews were audio recorded and transcribed verbatim.

Interview data and publicly available government documents (e.g., the Kenya constitution (2010), the Pharmacy and Poisons Act and the NGO Coordination Act), peer reviewed and grey literature and newspapers archives were read iteratively. Data were coded into key themes employing an open coding process using Atlas ti v. 7.5.9 (2015) qualitative software. Data coding and recoding was an ongoing process as new and more refined patterns of engagement between exogenous and state actors emerged [34]. A codebook with operational definitions was created to maintain consistency in the coding process (Appendix A).

A semantic analysis of key informant transcripts was also conducted. A semantic analysis investigates how words are used in context and their relationship to one another [34]. Words used by key informants to describe their perceptions of pharmacovigilance priorities at federal, county, and corporate levels; governance related to the priority setting process; the nature of interactions among global, national, county and municipal actors pertaining to pharmacovigilance were analyzed. An analysis of linguistic connectors used by key informants, provided insight into their perspectives of causality ‘(because)’, conditional relations ‘(since)’, contingent relations ‘(if-then, rather than): (as soon as)’ and temporal relations ‘(before, now)’ related to how, when and why state and exogenous actors interacted pertaining to pharmacogovernance [34].

**Results**

**Exogenous actors’ motivation for advancing pharmacovigilance in Kenya**

The semantic analysis of key informants interviewed suggested that exogenous actors have begun to prioritize pharmacovigilance. According to one IGO/INGO interviewed, “there are very many good reasons to expand and extend the coverage of pharmacovigilance because the chance of finding rare adverse reactions is directly proportional to the population exposed and the danger that is being gathered. In terms of the variability of the problems, they will look very different.

### Table 1 Exogenous actors contributing to pharmacogovernance (Continued)

| Uppsala Monitoring Centre (UMC-Sweden); WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance (UMC-Africa) | PPB and MoH SAGs | WHO International Centre for Drug Monitoring | Kenya National Pharmacovigilance Guidelines- Draft [6] |
| --- | --- | --- | --- |
| International NGOs | Mission for Essential Drugs (Meds) | PPB and MoH SAGs | Meds | Kenya National Pharmacovigilance Guidelines- Draft [6] |
| Health Action International-Africa (HAI-Africa) | PPB and MoH SAGs | HAI-Africa | Kenya National Pharmacovigilance Guidelines- Draft [6] |
| Pharmaceutical Industry | PPB and/or MoH SAGs | Various drug companies | Policy, law and regulation (QPPV, PSUR) [5, 6] |

### Table 2 Characterization of key informants interviewed

| Key Informants Interviewed | Sector | Region |
| --- | --- | --- |
| 2 | Regulatory | National |
| 4 | Health/Pharmacy Administrators | County |
| 2 | Multinational Pharmaceutical Companies | Global |
| 1 | Domestic Pharmaceutical Company | National |
| 4 | IGO/INGO | Global |
in different populations and different cultural situations (IGO/INGO-2). For this reason, they have funded active surveillance studies as well as pharmacovigilance training. As a member of the Uppsala Monitoring Centre, PPB has received access to data analyses of case reports and the Vigibase® data management system. Although historically their priorities for commodities management have focused on access rather than pharmacovigilance, the global actors that were interviewed actively advocated for pharmacovigilance within the programs that they managed because “...you can see basically that's commodities management. Pharmacovigilance is just one [part] of it. I talk passionately when I advocate for pharmacovigilance. I say that we have to match ACCESS with SAFETY” (IGO/INGO-5).

International donors' priorities for pharmacovigilance have influenced domestic priorities at the regulatory authority and county level. Input from the WHO contributed to the expansion of the Pharmacy and Poisons Board priorities to include medicines safety [13].

“There was a time when we [only] wanted medicines to be available. That was the biggest want. But now we want to go past the availability debate to the safety of these drugs.”- PPB-1

“There could be [a relationship between priorities for pharmacovigilance in the county and global actors] because many times when we conduct this postmarket surveillance we are funded. So there could be a connection in that these donors might be funding it.” - County-4

Exogenous actors’ engagement with the Government and the Pharmacy and Poisons Board has focused on strengthening pharmacogovernance in Kenya to enhance postmarket drug safety. An Indicator-based Pharmacovigilance Assessment Tool (IPAT) was developed by USAID/MSH [35] and in 2015, the WHO published an up-to-date comprehensive tool for assessing pharmacovigilance systems [36]. In addition to guidelines for pharmacovigilance system assessment [37], they have supported the establishment of pharmacovigilance centres in Kenya, and other countries in Africa; disseminating their policy norms through them.

“Our work plan is also strengthening those that have come on board or there is no point in being on board. And, helping them with systems issues like policies... So I came to them championing partnerships where they are drumming up support from those around them.” -IGO/INGO-3

State and exogenous actors’ perceptions of pharmacogovernance and drug safety
Pharmacogovernance affects governing structures; institutional authority; implementation of law and policy; enforcement of laws, norms, policies and processes; and resources to advance drug safety.

The results of our semantic analysis revealed that key informants’ perceptions of the relationship between governance and pharmacovigilance converged regarding the desire for harmonization of policy and laws for drug approval and postmarket requirements. Key informants’ perceptions regarding other facets of pharmacogovernance varied according to type of actor interviewed. International NGOs used the most words to describe governance; reflecting their perception of its importance. The importance of good governance is also widely disseminated in their literature [19, 38–40]. A code of ethics to prevent corruption, good manufacturing processes, spontaneous ADR reporting and sentinel reporting sites are described as requisites of good governance pertaining to pharmaceuticals [37, 38, 40]. Words that were used by IGO/INGOs in their response to interview questions about governance included accountability, transparency, budgets and funding, autonomy, leadership, contracts, rules and directives.

The words that PPB key informants used in their response to interview questions related to governance reflects their perception that achieving their mission ‘to safeguard the health of the public by ensuring that medicines and health products comply with acceptable standards of quality, safety and efficacy’ is affected by the National Pharmaceutical Policy, institutional authority and capacity. Kenya’s pharmaceutical sector has been characterized as having a weak infrastructure, conflicting laws and weak enforcement of laws governing pharmaceuticals [13, 19]. Enforcement of pharmacovigilance has been challenged because “the law is not explicit on pharmacovigilance issues” (PPB 02). The words that representatives of PPB used related to governance included constitution, policy, budget and revenue. The emphasis on resources reflects the perception that current budget and staffing for pharmacovigilance is insufficient to cover pharmacovigilance, postmarket surveillance, and medicines information for 2 million Kenyans (PPB-01).

Pharmaceutical representatives interviewed held divergent perceptions of their companies’ responsibility for pharmacogovernance. In regards to accountability for drug safety, all of the pharmaceutical representatives that were interviewed perceived that their primary responsibility was to adhere to corporate pharmacovigilance policies. They perceived it was in their companies’ interest to influence PPB norms and policies pertaining to ADR reporting. The words used by pharmaceutical
companies to describe governance emphasized policy and standard operating procedures.

“So with the corporate governance we've got policies and procedures, worldwide policy and procedures, we've got SOPs that are global.” - Pharma-1

Only one of the pharmaceutical company representatives interviewed highlighted the importance of a corporate governance policy for company-wide participation in pharmacovigilance.

Patterns of interactions among state, non-state, and external actors’ influencing pharmacogovernance and pharmacovigilance

We analyzed the patterns of engagement between exogenous and state actors and found examples of dependent (advocacy, delegation, empowerment and hierarchy), independent (autonomy and fragmentation) and interdependent (collaboration, cooperation, and consultation) patterns of engagement. Dependent and interdependent patterns of engagement were found to be associated with strengthening pharmacovigilance through capacity building; pharmacovigilance priority setting; advocacy for policy, law, or regulation; stakeholder coordination; and local empowerment for pharmacovigilance. Delegation was associated with strengthening pharmacovigilance with respect to exogenous actors’ aim to develop Pharmacy and Poisons Board into a regional actor for pharmacovigilance for the purpose of transferring to Kenya the responsibility for building regional capacity. The effect of specific modes of engagement on pharmacogovernance is shown in Table 3.

Interactions strengthening pharmacogovernance

Exogenous actors have both catalyzed and strengthened some of the proposed changes to pharmaceutical policies, laws and regulations in Kenya [6, 10, 19]. They engaged in advocacy with government, Pharmacy and Poisons Board and other non-state stakeholders to shape PPB and Ministry of Health policy preferences regarding the Pharmacy and Poisons Act Amendment and adoption of a National Pharmacovigilance System. They have engaged in consultative interactions for the purpose of sharing information about pending legislation and changes in existing legislation.

"[We] liaise with government to get to know what needs to be done, what legislation, what laws need to be put in place, what reviews need to be made, what needs to be taken to Parliament just to get the legislation in law, and all that. You know, negotiating at the government level to make sure the right laws get passed.” - IGO/INGO-1

However, one non-state actor expressed frustration with the pace of change suggesting that it had hindered pharmacovigilance “because once it goes through Cabinet they change many things so there are many things that I have had to pull, because of these new changes as far as governance goes to tweak implementation. I can't implement it under the previous budget because of new laws” (IGO/NGO-5).

The IGO/INGOs key informants advocated for greater accountability by pharmaceutical manufacturers because, “industry is manufacturing medicines and releasing them out to the market and thinks once it is sold...to them it is done” (IGO/INGO-1). The need for greater industry accountability was echoed by a pharmaceutical industry key informant who reported that companies that invested in pharmacovigilance were competing against companies that did not; suggesting that self-regulation was ineffective.

Despite Kenya’s adoption of global actors’ norms for pharmacovigilance, key informants that were interviewed asserted that the basis for engagement between state and exogenous actors in Kenya was autonomy. As such, they claimed that they merely ‘suggested’ policy, laws, regulations and norms for adoption. They respected that “[low- and middle-income countries (LMICs)] know where they are going” (IGO/INGO-5). Rather than drive a specific agenda, key informants claimed that they responded to requests for support by local/national governments when they had overlapping interests.

"We are aware that individual countries or regions need to develop, like European Commission did back when the European Union did not have an EU-legislation on pharmacovigilance. We also are aware that this has to evolve.” – IGO/INGO-3

Exogenous actors’ engagement with the PPB was largely consultative regarding setting pharmacovigilance priorities “to determine what our focus areas really should be and once determined, support aspects of quality assurance of medicines issues and aspects of ensuring that patient safety is optimal” (IGO/NGO-1). Data analyzed from actors at the policy level (government), implementation level (health facilities), oversight level and the private sector showed that, “agreed milestones and timelines of giving this support” were established as a consequence of the consultations (IGO/NGO-1). One key informant stated that when meeting with the County Health...
Executive, “we were looking out for all of these things together, the commitment they are making, and listening to the plans that they have and telling them what we are looking out for and what we plan to do in the future.” (IGO/NGO-1)

Kenya PPB, IGO and INGO key informants’ policy preferences for pharmacovigilance are compared in Table 4.

Some exogenous actors have engaged in collaborative interactions with the counties to provide resources to support greater ADR reporting and to facilitate dissemination of ADR reports submitted.

“We normally support that because health care workers report and the reports are laying [around] in the facilities because they don’t necessarily have a system of how they are getting to the Pharmacy and Poisons Board. So that is both for ADRs and reports for the whole country not just in certain counties.” - IGO/INGO-5

Several key informants reported that IGO/INGOs’ advocacy in Kenya was part of a broader agenda, to strengthen pharmacovigilance regionally. A network of pharmacovigilantes that have been trained in Kenya have been delegated the responsibility to educate Kenya’s neighbours, build local capacity for pharmacovigilance and advocate for regional strengthening of pharmacovigilance systems.

PPB will be able to implement this agenda in their capacity as a Regional Centre of Regulatory Excellence (RCORE) for pharmacovigilance.

“We officers from PPB are part of our outreach strategy, part of Pharmacovigilantes Sans Frontiers... and it’s working. The more you can influence big countries the more you use them to influence those around them.” - IGO/INGO-3

**Interactions hindering pharmacogovernance**

Certain interactions negatively influenced pharmacogovernance, specifically policies for ADR reporting and corporate accountability for pharmacovigilance. One key informant reported that the PPB sought industry input regarding policy changes and was responsive to industry requests. Industry input was sought on the 2014 draft legislation to require each pharmaceutical company to employ a qualified person for pharmacovigilance (QPPV). Another informant reported that PPB “obviously wants to engage with industry, wants collaboration, and wants our input” (Pharma-1). The key informant reported further that PPB had been responsive to previous requests including a request to modify the schedule for completing the Periodic Safety Update Report (PSUR) to harmonize with the reporting schedule for regulatory authorities in the European Union.

---

**Table 3 The modes of engagement between domestic and exogenous actors and the effect on pharmacogovernance**

| Pharmacogovernance domains                                      | Modes of Engagement | Advocacy | Autonomy | Collaborative | Consultative | Delegated | Empowerment | Fragmented |
|-----------------------------------------------------------------|---------------------|----------|----------|--------------|--------------|-----------|-------------|------------|
| Policy, law, regulation (Governing structures, norms,          | +/-                 | +/-      | +        | +            | +            |           | +           |            |
| policy instruments, practices, institutional authority)        |                     |          |          |              |              |           |             |            |
| Accountability & Transparency                                  | +                   |          |          |              |              |           |             |            |
| Participation & Representation                                  | +/-                 |          |          |              |              |           |             |            |
| Equity & Inclusiveness (Distribution of resources for          | +                   |          |          |              |              |           |             |            |
| pharmacovigilance)                                            |                     |          |          |              |              |           |             |            |
| Ethics (Policies to safeguard patient interests)               | +/-                 |          |          |              |              |           |             |            |
| Effectiveness & Efficiency (System integration & communication)|                     |          |          |              |              |           |             |            |
| Responsiveness (Risk communication)                            |                     |          |          |              |              | +         |             |            |
| Intelligence & Information (e-reporting technology, risk       | +                   |          |          |              |              |           |             |            |
| communication)                                                |                     |          |          |              |              |           |             |            |
| Stakeholder Coordination (Pooled resources, network mobilization, communication network) | +                   |          |          |              |              |           |             |            |

Enable pharmacovigilance (+), Hinder pharmacovigilance (-)
|                  | PPB County | Generic Pharma | Multinational Corporation | INGO (non-state) | IGO (external actors) |
|------------------|------------|----------------|---------------------------|-----------------|-----------------------|
| • Drug safety in addition to availability | • Drug safety in addition to access | • Substandard, fake, and counterfeit drugs | • Harmonization of reporting requirements | • Drug safety in addition to access | • Increase policy makers and donors awareness of the connection between access and PV Health systems strengthening |
| • Increase ADR reporting (public & health workers) | • Detect and report ADRs | • Harmonization of reporting requirements | • Training for all employees to increase awareness of PV | • PV Systems strengthening | • Active surveillance |
| • Poor quality medicines reporting | • Detect and report poor quality medicines | • PV as a clearly defined role | • Maintain compliance with national PV requirements | • Capacity building to improve the quantity and quality of ADR reports | • Ensure quality of products procured |
| • Active surveillance | • Monitoring quality of medicines | • Spontaneous reporting only-no mandatory reporting | • Quality testing of drugs entering through ports | • PV Legislation (e.g., qualified PV personnel in each drug company) | • Harmonization of PV systems and reporting tools, nationally |
| • Ensure quality of products in the market | • Strengthen PV systems | • Establish PV systems | • Health facilities know proper storage conditions for medicines | • Systems surveillance approach to PV | • Capacity building to improve the quantity and quality of information that supports decision making. |
| • Harmonization of PV system | • Pharmaco-surveillance of drugs targeted by public programs (TB, family planning, and malaria; high morbidity, commonly used) | • Adoption of a National Pharmacovigilance Policy | • Quality testing of drugs entering through ports | • Synchronize priority areas with PPB and other IGO/INGOs | • Negotiate with government to achieve an appropriate legal framework for PV |
| • Increase awareness of PV | • Quality testing of drugs entering through ports | • • PV Legislation (e.g., qualified PV personnel in each drug company) | • Establish PV systems | • Systems surveillance approach to PV | • Support for pharmaceutical policies and laws |
| • Capacity building | • Health facilities know proper storage conditions for medicines | • Harmonization of reporting requirements | • Establish PV systems | • Adopt a National Pharmacovigilance Policy | • All countries have PV systems. |
| • PV Legislation (No explicit PV laws) | • Health facilities know proper storage conditions for medicines | • Harmonization of reporting requirements | • Establish PV systems | • Global populations are covered by PV activities. | • Global populations are covered by PV activities. |
| • Kenya as a leader in patient safety-a Centre of Excellence | • Harmonization of reporting requirements | • Harmonization of reporting requirements | • Establish PV systems | • Participation in UMC is expanded to increase the chance of finding rare adverse reactions | • Participation in UMC is expanded to increase the chance of finding rare adverse reactions |
| • Facilitate ease of reporting | • Harmonization of reporting requirements | • Harmonization of reporting requirements | • Establish PV systems | • Redefine the focus of PV to include old issues with older drugs (Evergreening) | • Redefine the focus of PV to include old issues with older drugs (Evergreening) |
| • Take action on ADR reports | • Harmonization of reporting requirements | • Harmonization of reporting requirements | • Establish PV systems | • Negotiate with government to achieve an appropriate legal framework for PV | • Negotiate with government to achieve an appropriate legal framework for PV |
| • Introduce industry reporting | • Harmonization of reporting requirements | • Harmonization of reporting requirements | • Establish PV systems | • Support for pharmaceutical policies and laws | • Support for pharmaceutical policies and laws |

Moscou and Kohler Globalization and Health (2017) 13:20
The patterns of engagement between exogenous and domestic actors and their effect on the pharmacogovernance domains are shown in Fig. 1.

**Interactions strengthening pharmacovigilance**
Non-state and external actors used the power of their existing networks to advocate for the creation of new networks for the purpose of mobilizing resources to strengthen pharmacovigilance and active pharmaco-surveillance. Pooling resources expanded capacity for pharmacovigilance thus creating a better value for limited donor dollars. The European Commission, WHO and UMC worked with PPB to implement Cohort Event Monitoring, “they provided seed money and they supported us to develop the clinical trials registry in collaboration with the Kenya Medical Institute” (PPB-2).

“We’ll pool [resources]. Like that Cohort Event Monitoring program, the HIV and us…We work together. They have put in some support or even technical assistance for that. During the implementation of that program we draw on that money to support it. We also use the money from there to train the sites”. - IGO/INGO-5

IGO/INGO advocacy contributed to developing a cadre of advocates for pharmacovigilance whom they nurtured and exposed to pharmacovigilance best practices and training to build confidence and competence. The term *pharmacovigilantes* was used to describe individuals who advocated for pharmacovigilance. The manner in which global actors courted and nurtured the pharmacovigilantes is exemplified by the following quote:

“In Kenya in particular, one of the key people we identified very early on in Pharmacovigilantes Sans Frontiers, we courted him and nurtured him... we provided exposure to best practices outside and in Kenya starting from way back in 2004 and started sowing the seeds. So through our direct efforts there is a pharmacovigilance centre and [it]...
became affiliated with the WHO program. And now they’re one of the leading countries in Africa.” - INGO/NGO-2

Interactions hindering pharmacovigilance

Some pharmaceutical companies’ actions to influence Kenya’s draft legislation requiring a qualified person for pharmacovigilance (QPPV) may negatively impact both pharmacogovernance and pharmacovigilance. The proposed legislation would require each pharmaceutical company operating in Kenya to employ pharmacovigilance personnel. In the absence of QPPV legislation, the multinational corporations (MNCs) interviewed had assigned a single individual to oversee more than 25 countries. One key informant was responsible for overseeing 42 African countries. Corporate decisions to appoint a regional head for pharmacovigilance rather than a country head and to oppose QPPV legislation impedes patient safety and therefore contradicts beneficiary.

“It’s impossible for a pharmaceutical company to have a pharmacovigilance person, totally responsible for pharmacovigilance in each country. So, they [PPB] have [proposed] a stricter guideline which I have written back and said we can’t do that.” - Pharma-1

The relationship between pharmacovigilance and patterns of engagement between state and exogenous actors is shown in Fig. 2.

Discussion

Pharmacogovernance and pharmacovigilance in Kenya mirror other low- and middle income countries [1, 20, 22]. Many Sub-Saharan Africa countries lack a national pharmacovigilance system, have limited infrastructure, human resources, training and capacity to detect and analyze drug safety signals [20, 22]. A survey of Sub-Saharan Africa countries found that fewer than one third had laws and regulations to mandate pharmacovigilance activities [20]. Pharmaceutical safety issues are not confined to regional borders. Risks related to pharmaceutical consumption are multi-jurisdictional because medicines are produced and sold in a global marketplace [13]. Medicines manufactured in Kenya are marketed to other countries in the East Africa Community and medicines manufactured by multinational corporations are available for sale in Kenya. Network Governance Theory suggests that under such conditions policy actors will be motivated to come together in order to contribute to shaping governance.

The research findings illuminate how Kenya’s governance, that permits delegation of authority to non-state implementing partners, creates space for exogenous actors to influence normative policy, policy instruments and practices that affect pharmacogovernance and pharmacovigilance. Brass (2012), found that NGOs in general are well integrated into Kenya’s governance and the line between government policy makers and NGO implementing partners is blurred.

Our semantic analyses showed that exogenous and domestic actors’ perceptions of governance reflected their divergent interests in shaping the direction of pharmaceutical policy. Whereas IGO/INGOs linked accountability with pharmacogovernance, and described their actions to contribute to shared governance as a mechanism to advance pharmacovigilance globally, some county actors and pharmaceutical firms (domestic and MNC) perceived accountability as the responsibility of others, such as the PPB. This finding is significant in terms of drug safety and suggests that stronger pharmacogovernance between levels of government and among domestic and exogenous actors is needed. Despite differences in the words attributed to governance expressed by sector representatives, our finding that there was shared interest in pharmacogovernance related to shaping rule of law and harmonization of policies among IGO/INGOs, PPB and pharmaceutical firms interviewed is important. The implication of this finding is that regulatory authorities, pharmaceutical firms and global actors can converge around a common solution (e.g., strengthening regulatory governance for medicines safety) despite divergent problem definition when interdependency is perceived to be beneficial.

All of the key informants interviewed perceived engaged engagement among state, non-state or external actors was generally positive; likely because exogenous actors’ priorities for pharmacovigilance were adopted in tandem with domestic interests. Moreover, the Pharmacy and Poisons Board exercised autonomy over its choice to adapt or adopt suggested policy norms. As an example, in designing its e-reporting system, PPB adapted WHO norms for pharmacovigilance by adding a feature for reporting suspected poor quality medicine. PPB signaled its priority to expand the definition of pharmacovigilance beyond ADRs.

We found that in Kenya, pharmacogovernance and pharmacovigilance are strengthened by fostering interdependent engagement among county, national and exogenous actors. Specifically, engagement among the Pharmacy and Poisons Board, Ministry of Health and exogenous actors based on collaboration and advocacy favoured resource allocation by exogenous actors to support pharmacovigilance and reduce drug safety risk.
Through engagement characterized as advocacy, governance networks comprised of domestic and exogenous actors are providing support for expansion of PPB’s regulatory authority and amendments to the Food, Drug and Chemical Substance Act and Pharmacy and Poisons Act in order to strengthen pharmacogovernance. Neither of the Acts included language on pharmacovigilance when first passed.

The state-exogenous actors’ relationship regarding the pharmacogovernance domain ‘Policy, Law, and Regulation’ was mostly positive, however this study found efforts by some exogenous actors to limit regulatory reforms. Pharmaceutical industry consultations with PPB, that aimed to discourage adoption of requirements for a QPPV on the grounds that the policy was unnecessary and too costly, impeded pharmacovigilance.

We argue that pharmacovigilance may also be hindered by exogenous actors’ policy preferences for the harmonization of regulatory requirements for drug registration because the aim of policies promoted by the AMRH and the EAC is to reduce trade barriers rather than pharmacovigilance [7, 41]. Although this study found convergence in key informants’ perceptions of regulatory harmonization, regardless of the sector they represented, the benefits of regulatory harmonization have been contested in the literature due to the trend to harmonize to the lowest standard rather than raise regulatory requirements, even in high income countries [42, 43].

![Fig. 2 Patterns of interactions between domestic and exogenous actors affecting pharmacogovernance](image-url)
Some of the deficits that were found in the pharmacogovernance were not overcome by state-exogenous actors’ engagement. We did not find evidence that exogenous actors influenced legislation to address the lack of resources for pharmacovigilance. However, we found strong engagement among exogenous actors that had a positive effect on mobilizing donor resources for pharmacovigilance. Interdependent and dependent engagement led to resource allocation for active pharmacosurveillance (e.g., CEM and TSR) as well as innovations in data collection and risk communication (e.g., e-reporting and mobile phone apps). Donor support for pharmacovigilance was commonly cited as critical by key informants because resources available for pharmacovigilance are limited in Kenya and other LMICs [20, 44, 45]. Exogenous actors including USAID, MSH, WHO, Global Fund, and the Bill and Melinda Gates Foundation have recommended multi-sectoral engagement as a mechanism to expand resources for pharmacovigilance in resource-limited settings. Stakeholder coordination was likely strong because a sector-wide approach to development has been widely promoted by the neoliberal agenda since early 2000 [46]. We did not investigate whether certain global actors had more influence on pharmacogovernance than others; however, the literature suggests that technical and financial support from transnational policy actors is an incentive for the uptake of policy ideas in under-resourced LMI countries [47]. Thus, exogenous actors that offer financial and technical resources may have the greatest influence on pharmacogovernance in Kenya.

Conclusions
The research advances our understanding of the patterns of engagement between state and non-state actors pertaining to pharmacogovernance and pharmacovigilance. The literature on Network Governance Theory and risk governance posits that responsibility for managing risk should be shared between state and non-state actors [48, 49]. Our finding that domestic and exogenous actors contributed to pharmacogovernance through positive interdependent engagement is consistent with Network Governance Theory, which advances that multiple stakeholders’ varied perspectives expands the characterization of risk and the solutions that are considered. The research may be transferable particularly in regards to findings that indicate that the global policy community can support domestic policy actors’ efforts to strengthen pharmacovigilance in Sub-Saharan Africa through participation in governance networks. A global funding model could further advance national pharmacovigilance if funding is targeted to strengthen pharmacogovernance through the development of a national pharmacovigilance system; resource distribution for equitable pharmacosurveillance and the development of a nationwide risk communication network for rapid dissemination of drug safety information.

A framework for assessing pharmacogovernance would support policy makers’ evidence-based decision making regarding investments to strengthen capacity for pharmacovigilance; important when resources are limited [1, 50]. It would also support policy to address inequities in pharmacovigilance particularly in rural geographic regions that are disproportionately disadvantaged; having fewer hospitals and pharmacosurveillance units than urban centres [1, 22, 50].

The research results suggest that caution is warranted regarding the sole use of exogenous actors to fill a deficit in capacity for pharmacovigilance. It leaves Kenya vulnerable to: 1) a fragmented pharmacovigilance system; 2) ad hoc, drug specific pharmacosurveillance; 3) cross purpose interests; and 4) exogenous actors’ shifting priorities. For although exogenous actors are likely to continue to advocate for pharmacovigilance while interests align, Kenya is already experiencing the effect of shifting priorities that have reduced donor funding. Whereas key informants interviewed recognized Kenya’s autonomy to adopt global actors’ norms, less consideration was given to donors’ autonomy to determine to whom to provide their resources and support. Therefore, the research suggests that strengthening pharmacogovernance amongst national and subnational government levels will best advance postmarket drug safety in low- and middle income countries.

Limitations and future research
The key informants interviewed for this study represent an information-rich sample of policy makers in IGO/INGOs, government and pharmaceutical firms in Kenya. The data collected represent a range of views pertaining to state and exogenous actor engagement that is limited to pharmacogovernance. We were unable to interview representatives from the faith-based sector. Although data provided in interviews about this sector were reported in the literature reviewed and the documents analyzed, additional studies are suggested to capture the perspectives of representatives from the faith-based sector. Additional studies are needed to evaluate whether the study findings are transferable to other sectors where state/non-state governance networks operate.
Appendix A

Table 5 Patterns of interactions and pharmacogovernance codebook

| Patterns of interactions | Code     | Definition                                                                 | Example                                                                                                                                 |
|--------------------------|----------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Autonomy                 |          | Self-governing or acting independently.                                     | So that's the thing with devolution. You can make the decision. You don't have to wait for somebody to tell you what you do if this or that.    |
| Advocacy                 |          | Motivates change in policies, priorities and/or resource allocation to advance pharmacovigilance | The country can identify it [pharmacovigilance] as a priority but if it had not been an important focus area from Washington, then it becomes difficult for the local region to get sufficient resources for it. |
| Collaborative            |          | Formal or non-structured partnerships for the joint development of programs, policies, and pharmacovigilance resources that strengthen pharmacovigilance. | [We developed a] Master's in pharmacy, pharmacoeqi, and pharmacovigilance. And we collaborated with the University of Nairobi and the University of Washington. I got it up and running now. |
| Consultative             |          | Engages external advisors in pharmacovigilance decision-making.              | So you want to work closely with the County Directors of Health, the County pharmacists so that you can get more information from them. And share with them what you are seeing in other counties because they will only see what is available in the county. |}

| Cooperator               |          | Agreement made between federal, state, county, or global actors to work together or jointly support a specific issue. | [B]ilateral cooperation is agreed among the countries. We may or may not take part. We may suggest some field for cooperation among two countries. |
| Delegate                 |          | Give oversight of pharmacovigilance activities to another entity or group (e.g., national regulatory authority to county/state dept. of health; MoH to NGO; nurses to pharmacists). | The staff in the county, they're mostly drug inspectors; there are no pharmacovigilance case [workers]. So in case the [regulatory authority] wants to conduct pharmacovigilance they will contact me to coordinate the activities in Coast region. |
| Fragmented               |          | Interealated PV responsibilities and overlapping functions with limited integration of PV activities and accountability. | Yeah, it's quite complicated for faith-based organizations, at least for the Catholic church. They have their own system. |
| Hierarchical             |          | Organized according to a series of levels with different importance or status, each subordinate to the one above it. | [B]ecause as a global group I don't report here. My director is based in headquarters. I have a dotted line to the country manager but my group reports directly to headquarters. |

Acknowledgements

None.

Funding

Global Health Student Research Award, Dalla Lana School of Public Health, University of Toronto.

Availability of data and materials

Not applicable.

Authors’ contributions

KM conceived the study design, conducted all key informant interviews, was responsible for data extraction, analysis, drafted the paper and made revisions suggested by the co-author. JCK read and contributed to paper drafts. Both authors read and approved the final paper.

Competing interests

The authors have no financial or non-financial competing interests to declare.

Consent for publication

Key informants provided prior written consent to publish information they provided in their interview.

Ethics approval

Ethics approval was obtained from the University of Toronto, Canada (#29254) and Moi University, Kenya (#0001151). Key informants provided prior written consent to participate in the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON M5S 3M2, Canada. 2Munk School of Global Affairs1 Devonshire Place (At Trinity College), Toronto, ON M5S 3K7, Canada. 3Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, ON MST 3M7, Canada. 4WHO Collaborating Centre for Governance, Accountability and Transparency for the Pharmaceutical Sector, University of Toronto, 144 College Street, Toronto, ON M5S 3M2, Canada. 5School of Health Policy and Management, Faculty of Health, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada.

Received: 1 August 2016 Accepted: 12 January 2017

Published online: 23 March 2017

References

1. Moscou K, Kohler J, MaGahan A. Governance and pharmacovigilance in Brazil: a scoping review. Journal of Pharmaceutical Policy and Practice. 2016;9(3). doi:10.1186/s40545-016-0053-y.
2. Garuba H, Kohler J, Huisman A. Transparency in Nigeria’s public pharmaceutical sector: perceptions from policy makers. Globalization and Health. 2009;5(14). doi:10.1186/1744-8603-5-14.
3. Baghdadi-Sabeti G, Cohen-Kohler J, Wondermagengehu E. Measuring transparency in the public pharmaceutical sector- assessment instrument.
Geneva: World Health Organization, Departments of Essential Medicines and Pharmaceutical Policies & Ethics, Equity, Trade and Human Rights; 2009.

4. Mackey T, Liang B. Combating healthcare corruption and fraud with improved global health governance. BMC Int Health Hum Rights. 2012;12(23):1–7. doi:10.1186/1472-698X-12-23.

5. Kohler J, Martínez M, Petkó M, Sale J. Corruption in the pharmaceutical sector: diagnosing the challenges. UK: Transparency International; 2016.

6. Kenya PPB. Guidelines for the national pharmacovigilance system in Kenya. Nairobi: Ministry of Medical Services and Ministry of Public Health and Sanitation; 2009.

7. Ministry of Health. Transforming Health: Accelerating Attainment of Universal Health Coverage. Kenya Health Sector Strategic and Investment Plan (KHSSP) July 2014- June 2018. Nairobi. nd. www.health.go.ke.

8. PPB Kenya. Pharmacy and Poisons Board Mission and Vision. 2015. www.pharmacyboardkenya.org. Accessed 30 Jul 2015.

9. Republic of Kenya. The Constitution of Kenya, 2010. Nairobi: National Council for Law Reporting with the Authority of the Attorney-General. 2010. www.kenyalaw.org.

10. Sessional Paper No.6 of 2012 on the Kenya Health Policy 2012–2030 (DRAFT) National Development and Vision 2030. Office of the Prime Minister Ministry of State for Planning.

11. Ministry of Health. Pharmacy and poisons board strategic plan 2014-2019. Nairobi: Republic of Kenya Ministry of Health; 2015.

12. Olsson S, Nilsson E, Pal S. Monitoring Medicines Project Final Report 2009–2013. Brussels: European Commission FP7/2013. 2013. www.monitoringmedicines.org.

13. Sessional Paper No. 1 on the National Pharmaceutical Policy. Office of the Prime Minister Ministry of State for Planning. 2010.

14. Brass JN. Blurring Boundaries: The Integration of NGOs into Governance in Kenya. Governance: An International Journal of Policy, Administration, and Institutions. 2012;25(2). doi:10.1111/j.1468-0491.2011.01553.x.

15. National Council of NGOs. The NGO Council Member List. National Council of NGOs. 2014; www.thengocouncilkenya.org/index.php/resources-and-publications/downloads.htm Accessed 6 Jun 2016.

16. Kagawa RC, Anglemeyer A, Montagu D. The scale of faith based organization participation in health service delivery in developing countries: systemic review and meta-analysis. PLoS One. 2012;7(11):e4857. doi:10.1371/journal.pone.004857.2011.01553.x.

17. Kenya Health Facilities list with services as of October 5, 2015. e-Health Provision Assessment Survey 2010. Nairobi: National Coordinating Agency for Population and Development by the SPS Program. Arlington: Management Sciences for Development by the SPS Program. Arlington: Management Sciences for Health; 2009. http://apps.who.int/medicinedocs/en/d/Js21303en/.

18. National Coordinating Agency for Population and Development (NCAPD) [Kenya] MoHMSK, Ministry of Public Health and Sanitation (MOHPS) [Kenya], Kenya National Bureau of Statistics (KNBS) [Kenya], ICF Macro, Kenya Service Provision Assessment Survey 2010. Nairobi National Coordinating Agency for Population and Development, Ministry of Medical Services, Ministry of Public Health and Sanitation, Kenya National Bureau of Statistics, and ICF Macro, 2011. http://dhusprogram.com/pubs/pdf/SPA17/SPA17.pdf. Accessed 21 Nov 2015.

19. Mbinyo R, Okello D, Kimani F. Experience with supporting pharmaceutical policies and systems in Kenya: Progress, lessons and the role of WHO (WHO/EMP/MPC/2010.2). Geneva: World Health Organization; 2010. http://www.who.int/medicines/publications/emp_mpc/2010.2/en/.

20. Strengthening Pharmaceutical Systems (SPS) Program. Safety of medicines in Sub-Saharan Africa: assessment of pharmacovigilance systems and their performance. Arlington: US Agency for International Development by the Strengthening Pharmaceutical Systems (SPS) Program; 2011.

21. Attaran A, Barry D, Basheer S, Bate R, Benton D, Chavvin J, et al. How to achieve international action on falsified and substandard medicines. BMJ. 2012;345:e381. doi:10.1136/bmj.e381.

22. Olsson S, Pal S, Petkó M. Pharmacovigilance in resource-limited countries. BMJ. 2012;345:e7381–60. doi.org:10.1136/bmj.e381.

23. Dua JY, Van Geertruyden J-P. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US food and drug administration and the European medicines agency? Trop Med Int Health. 2014;19(1):23–36.

24. Torfing J. Governance Networks. In: The Oxford Handbook of Governance. Levi-Faur D editor. 2012. doi:10.1093/oxfordhb/9780199560530.013.0007.

25. Blanco I, Lowndes V, Prattchett L. Policy networks and governance networks: towards greater conceptual clarity. Pol Stud Rev. 2011;9:297–308. doi:10.1111/j.1478-9302.2011.02399.x.

26. Aid Effectiveness Group. Government of Kenya. http://www.aideffectiveness.go.ke/. Accessed 22 Aug 2016.

27. AMRH. NEPAD Agency designates Regional Centres of Regulatory Excellence (RCOREs) for better regulatory capacity development in Africa. African Medicines Regulatory Harmonization Newsletter. 2014. http://spotdocom/doc/398645/nepad-agency-designates-regional-centres-of-regulatory-ex.

28. Non-governmental Organizations Co-ordination Act Chapter 134 Revised Edition 2012 [1990].

29. Public Benefits Organizations Act Revised Edition 2014 [2013]. Sect. 18 of 2013.

30. Menya W. State targeting us over support for Hague cases, civil society protests. Daily Nation. 2014. http://www.nationlive.co.ke/news/politics/Civil-Society-ICC-Hague-Cases-Jubilee-Government-/10642/496928-Ay4kdbr-/Andindexhtml.

31. Dependency: In: Oxford Companion to Politics of the World. Krieger J editor. Online ed: Oxford University Press; 2004. http://www.oxfordreference.com/view/10.1093/acref/9780195117394.001.0001/acref-9780195117394-e-0187?rskey=BOmdz8&result=353.

32. Interdependence: In: Oxford Companion to Politics of the World. Krieger J editor. Online ed: Oxford University Press; 2004. http://www.oxfordreference.com/view/10.1093/acref/9780195117394.001.0001/acref-9780195117394-e-0353?key=QfOSw8&result=353.

33. Trost IE. Statistically nonrepresentative stratified sampling: A sampling technique for qualitative studies. Qual Sociol. 1986;5:47–8. doi:10.1007/BF00988249.

34. Bernard HR, Ryan G. Analyzing qualitative data: systematic approaches. Thousand Oaks: SAGE publications, Inc.; 2010.

35. Strengthening Pharmaceutical Systems (SPS) Program. Indicator-Based Pharmacovigilance Assessment Tool: Manual for Conducting Assessments in Developing Countries. Submitted to the U.S. Agency for International Development by the SPS Program. Arlington: Management Sciences for Health; 2009. http://apps.who.int/medicinedocs/en/d/Js21303en/.

36. World Health Organization. WHO pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems. 2015.

37. UNAIDS | WHO. Technical Guidance Note for Global Fund HIV Proposals. 2011. http://www.unaids.org/sites/default/files/sub_banding/files/20110818_Technical_Guidance_Pharmaovigilance.pdf. Accessed 21 Feb 2016.

38. Anello E. A framework for good governance in the public pharmaceutical sector- working draft for field testing and revision. Geneva: World Health Organization; 2008.

39. Baghdadi-Sabeti G, Serhan F. WHO good governance for medicines programme: an innovative approach to prevent corruption in the pharmaceutical sector. Geneva: World Health Organization; 2010.

40. Organización Panamericana de la Salud. Buenas Prácticas de Farmacovigilancia [Good pharmacovigilance practices for the Americas]. Washington, D.C.2011. Report No.: Red PARF Documento Técnico No. 5.

41. House Team's Dilemma Over Proposed Parastatal Daily Nation. 2013 October 29.

42. Lexchin J. Harmony in drug regulation, but who's calling the tune? An examination of regulatory harmonization in health Canada. Int J Health Serv. 2012;42(1):119–36.

43. Abraham J, Davis C. Interpellative Sociology of Pharmaceuticals: Problems and Challenges for Innovation and Regulation in the 21st Century. Technology Analysis Stratag Manage. 2007;19(3):387–402.

44. Bill & Melinda Gates Foundation. A report to the safety and surveillance working group. 2013.

45. Moscou K, Kohler J, Lexchin J. Drug safety and corporate governance. Glob Health Gov 2013;5:56–79.

46. OECD. Proceedings from the OECD Expert Meeting on Regulatory Performance: Ex Post Evaluation of Regulatory Policies, September 22, 2003. Paris: OECD; 2003.

47. Béland D, Orenstein M. Transnational Actors and Public Policy. JSGS Working Paper Series. 2010:5–17.

48. Renn O, Klinek A, van Asselt M. Coping with complexity, uncertainty and ambiguity in risk governance: a synthesis. AMBIO. 2011;40:231–46. doi:10.1007/s13280-010-0134-0.

49. Renn O, Schweizer P. Inclusive risk governance: concepts and application to environmental policy making. Environ Policy Gov. 2009;19:74–85.

50. Jakovljevic M. BRIC's growing share of global health spending and their diverging pathways. Frontiers in Public Health. 2015;3. doi:10.3389/fpubh.2015.00135.